Medtronic (MDT)
$78.71
0.08 (0.10%)
MDT Stock Quote Delayed 30 Minutes
20 Best Dividend Stocks for 2013 and Beyond
Dividend investing is a process where capital is invested upfront with the intention to receive dividends for years to come and here are 20 names to get started
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
8.92M
Day's Range
$78.26 - $79.27
52-Week Range
$68.84 - $91.00
Dividend & Yield
$2.76 (3.51%)
MDT Stock Predictions, Articles, and Medtronic News
5 Medical Devices Stocks to Buy Now
This week, five Medical Devices stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
5 Medical Devices Stocks to Buy Now
The grades of five Medical Devices stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
7 Companies Increasing Dividends
Duke Energy, General Mills and Medtronic are among this week's top payout performers.
Lousy Jobs Report Follows a Rush of Layoff News
Friday's jobs report was utterly disappointing, but considering some of May's layoff news, we shouldn't be surprised -- now or in the future.
6 Flatlining Healthcare Stocks to Sell
Healthcare stocks are under pressure as patents expire and margins are pressed. Consider selling these 6 laggards from the portfolio.
